AU2009226161A1 - Use of pyrene to carry peptides across the blood brain barrier - Google Patents
Use of pyrene to carry peptides across the blood brain barrier Download PDFInfo
- Publication number
- AU2009226161A1 AU2009226161A1 AU2009226161A AU2009226161A AU2009226161A1 AU 2009226161 A1 AU2009226161 A1 AU 2009226161A1 AU 2009226161 A AU2009226161 A AU 2009226161A AU 2009226161 A AU2009226161 A AU 2009226161A AU 2009226161 A1 AU2009226161 A1 AU 2009226161A1
- Authority
- AU
- Australia
- Prior art keywords
- pyrene
- peptide
- agent
- conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3863408P | 2008-03-21 | 2008-03-21 | |
| US61/038,634 | 2008-03-21 | ||
| PCT/US2009/000613 WO2009117041A2 (en) | 2008-03-21 | 2009-01-30 | Use of pyrene to carry peptides across the blood brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2009226161A1 true AU2009226161A1 (en) | 2009-09-24 |
Family
ID=40974375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009226161A Abandoned AU2009226161A1 (en) | 2008-03-21 | 2009-01-30 | Use of pyrene to carry peptides across the blood brain barrier |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090238754A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2268314A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011517666A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102014967A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009226161A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2718860A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010010266A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009117041A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002320045B2 (en) | 2001-05-31 | 2008-05-08 | Adlyfe, Inc. | Misfolded protein sensor method |
| US20050026165A1 (en) | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| JP5097206B2 (ja) * | 2006-07-28 | 2012-12-12 | エイディーライフ インコーポレイティッド | 診断および治療のためのペプチドプローブ |
| US20090274621A1 (en) * | 2008-03-21 | 2009-11-05 | Adlyfe, Inc | Use of pyrene to carry non-peptide agents across the blood brain barrier |
| CN102365295A (zh) * | 2009-01-30 | 2012-02-29 | 阿德利夫股份有限公司 | 构象动力肽 |
| WO2013025261A2 (en) * | 2011-04-06 | 2013-02-21 | Georgia Tech Research Corporation | Fluorogenic peptide probes and assays |
| EP2712425A2 (en) | 2011-04-27 | 2014-04-02 | Adlyfe, Inc. | Ocular detection of amyloid proteins |
| JP6144673B2 (ja) | 2011-06-03 | 2017-06-07 | オフィディオン インコーポレイティド | 血液脳関門を通過して輸送するための組成物及び方法 |
| PL230602B1 (pl) | 2013-04-04 | 2018-11-30 | Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk | Kwas (E)-3-arylo-3-oksoprop-1-enylo-2-fosfonowy i jego pochodne, sposob ich wytwarzania oraz ich zastosowanie |
| PL223918B1 (pl) | 2013-05-28 | 2016-11-30 | Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk | 3-Arylo-2-fosforylo podstawione 1-indanony i sposób ich wytwarzania |
| WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| CA3073062A1 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| CN110759974B (zh) * | 2018-07-25 | 2021-11-09 | 中国医学科学院药物研究所 | 一种磷脂-聚乙二醇-狂犬病毒衍生肽聚合物,其制备方法及应用 |
| US10568907B1 (en) | 2018-10-09 | 2020-02-25 | Carol J. Buck | Methods of treating basal cell carcinoma and glioblastoma |
| US10369170B1 (en) | 2018-10-09 | 2019-08-06 | Carol J. Buck | Methods of treating basal cell carcinoma and glioblastoma |
| AU2020398216A1 (en) | 2019-12-04 | 2022-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing blood-brain barrier drug transport by targeting endogenous regulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822733A (en) * | 1985-05-28 | 1989-04-18 | Amoco Corporation | Lifetime-resolved assay procedures |
| US5260308A (en) * | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
| US5604198A (en) * | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
| US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| JP2001515044A (ja) * | 1997-08-14 | 2001-09-18 | ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 蛍光アミロイドAβペプチドとその使用 |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20030162698A1 (en) * | 1999-01-27 | 2003-08-28 | Alphonse Galdes | Methods and compositions for treating dopaminergic and gaba-nergic disorders |
| WO2001074374A1 (en) * | 2000-04-04 | 2001-10-11 | Mayo Foundation For Medical Education And Research | Methods for detecting plaques in vivo |
| US7311893B2 (en) * | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
| US7470420B2 (en) * | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
| JP4029041B2 (ja) * | 2001-01-10 | 2008-01-09 | アメリカ合衆国 | sFRPおよびsFRPと相互作用するペプチドモチーフならびにそれらの使用法 |
| GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| WO2002094191A2 (en) * | 2001-05-23 | 2002-11-28 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| US7851593B2 (en) * | 2002-01-04 | 2010-12-14 | Becton, Dickinson And Company | Binding proteins as biosensors |
| CN1688299A (zh) * | 2002-01-29 | 2005-10-26 | 普罗特米克斯公司 | 抑制细胞毒性蛋白构象异构体 |
| WO2005004794A2 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| US20050009109A1 (en) * | 2003-07-08 | 2005-01-13 | Stanford University | Fluorophore compounds and their use in biological systems |
| WO2005035549A2 (en) * | 2003-10-14 | 2005-04-21 | Kernel Biopharma Inc. | Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier |
| US20080038349A1 (en) * | 2004-02-17 | 2008-02-14 | Lamensdorf Itschak | Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase |
| WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
| EP1853915B1 (en) * | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| JP4295338B2 (ja) * | 2005-03-31 | 2009-07-15 | 財団法人野口研究所 | 質量分析法 |
| US7388747B2 (en) * | 2006-04-07 | 2008-06-17 | Inventec Corporation | Heat plate fixing structure |
| JP5097206B2 (ja) * | 2006-07-28 | 2012-12-12 | エイディーライフ インコーポレイティッド | 診断および治療のためのペプチドプローブ |
| US20090274621A1 (en) * | 2008-03-21 | 2009-11-05 | Adlyfe, Inc | Use of pyrene to carry non-peptide agents across the blood brain barrier |
-
2009
- 2009-01-30 AU AU2009226161A patent/AU2009226161A1/en not_active Abandoned
- 2009-01-30 WO PCT/US2009/000613 patent/WO2009117041A2/en not_active Ceased
- 2009-01-30 EP EP09722213A patent/EP2268314A2/en not_active Withdrawn
- 2009-01-30 JP JP2011500764A patent/JP2011517666A/ja active Pending
- 2009-01-30 CN CN2009801166660A patent/CN102014967A/zh active Pending
- 2009-01-30 US US12/363,254 patent/US20090238754A1/en not_active Abandoned
- 2009-01-30 CA CA2718860A patent/CA2718860A1/en not_active Abandoned
- 2009-01-30 MX MX2010010266A patent/MX2010010266A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2268314A2 (en) | 2011-01-05 |
| MX2010010266A (es) | 2010-12-14 |
| WO2009117041A2 (en) | 2009-09-24 |
| WO2009117041A3 (en) | 2010-01-07 |
| CN102014967A (zh) | 2011-04-13 |
| CA2718860A1 (en) | 2009-09-24 |
| US20090238754A1 (en) | 2009-09-24 |
| JP2011517666A (ja) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090238754A1 (en) | Use of pyrene to carry peptides across the blood brain barrier | |
| CA2750409C (en) | Peptide probes for amyloid beta protein | |
| JP5097206B2 (ja) | 診断および治療のためのペプチドプローブ | |
| US20090274621A1 (en) | Use of pyrene to carry non-peptide agents across the blood brain barrier | |
| US20120134922A1 (en) | Peptides whose uptake in cells is controllable | |
| US9795692B2 (en) | Ocular detection of amyloid proteins | |
| US20120282169A1 (en) | Detection and treatment of traumatic brain injury | |
| US10471163B2 (en) | Activatable fibrin-binding probes | |
| AU2015311836B2 (en) | Methods for detecting amyloid beta oligomers | |
| HK1164343B (en) | Conformationally dynamic peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |